BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 34030872)

  • 21. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
    Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
    J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of entecavir in preventing hepatitis B recurrence after liver transplantation.
    Xi ZF; Xia Q; Zhang JJ; Chen XS; Han LZ; Wang X; Shen CH; Luo Y; Xin TY; Wang SY; Qiu DK
    J Dig Dis; 2009 Nov; 10(4):321-7. PubMed ID: 19906113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention and risk factors of hepatitis B recurrence after living donor liver transplantation.
    Na GH; Kim DG; Han JH; Kim EY; Lee SH; Hong TH; You YK; Choi JY
    J Gastroenterol Hepatol; 2014 Jan; 29(1):151-6. PubMed ID: 24117684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.
    Cho JH; Lim JH; Park GY; Kim JS; Kang YJ; Kwon O; Choi JY; Park SH; Kim YL; Kim HK; Huh S; Kim CD
    Transpl Infect Dis; 2014 Apr; 16(2):295-303. PubMed ID: 24628837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of hepatitis B virus reactivation on the recurrence of HBV-related hepatocellular carcinoma after curative resection in patients with low viral load.
    Sohn W; Paik YH; Cho JY; Ahn JM; Choi GS; Kim JM; Kwon CH; Joh JW; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    J Viral Hepat; 2015 Jun; 22(6):539-50. PubMed ID: 25377516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis B virus DNA negativity acts as a favorable prognostic factor in hepatocellular carcinoma patients.
    Li X; Zhong X; Chen ZH; Xing YF; Wu DH; Chen J; Ma XK; Lin Q; Wen JY; Wei L; Wang TT; Ruan DY; Lin ZX; Wu XY; Dong M
    Asian Pac J Cancer Prev; 2014; 15(22):9635-41. PubMed ID: 25520081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors for hepatitis B virus recurrence after living donor liver transplantation: A 22-year experience at a single center.
    Bae SK; Akamatsu N; Ichida A; Maki H; Nishioka Y; Kawahara T; Hoshikawa M; Nagata R; Mihara Y; Kawaguchi Y; Ishizawa T; Arita J; Kaneko J; Tamura S; Hasegawa K
    Biosci Trends; 2021 Jan; 14(6):443-449. PubMed ID: 33239499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment.
    Kim JH; Sinn DH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Hepatology; 2017 Aug; 66(2):335-343. PubMed ID: 28012257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection.
    Chen CH; Hung CH; Hu TH; Wang JH; Lu SN; Su PF; Lee CM
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1984-92.e1. PubMed ID: 26073492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation.
    Saab S; Yeganeh M; Nguyen K; Durazo F; Han S; Yersiz H; Farmer DG; Goldstein LI; Tong MJ; Busuttil RW
    Liver Transpl; 2009 Nov; 15(11):1525-34. PubMed ID: 19877207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal.
    Manini MA; Whitehouse G; Bruce M; Passerini M; Lim TY; Carey I; Considine A; Lampertico P; Suddle A; Heaton N; Heneghan M; Agarwal K
    Dig Liver Dis; 2018 Sep; 50(9):944-953. PubMed ID: 29735294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.
    Pan HY; Pan HY; Song WY; Zheng W; Tong YX; Yang DH; Dai YN; Chen MJ; Wang MS; Huang YC; Zhang JJ; Huang HJ
    J Viral Hepat; 2017 Nov; 24 Suppl 1():29-35. PubMed ID: 29082652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
    Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
    Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Entecavir Combined With Short-term Hepatitis B Immunoglobulin in Preventing Hepatitis B Virus Recurrence in Liver Transplant Recipients.
    Zheng H; Zhu Z; Wang N; Qin J; Guo Y; Xu Z; Li X; Qi C; Yuan X; Wu W; Wang J; Liu L; Nashan B
    Transplant Proc; 2023 Mar; 55(2):408-412. PubMed ID: 36907782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
    Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
    J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
    Cholongitas E; Goulis I; Antoniadis N; Fouzas I; Imvrios G; Giakoustidis D; Giouleme O; Papanikolaou V; Akriviadis E; Vasiliadis T
    Transpl Infect Dis; 2016 Oct; 18(5):667-673. PubMed ID: 27421122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B.
    Fung J; Chan SC; Cheung C; Yuen MF; Chok KS; Sharr W; Chan AC; Cheung TT; Seto WK; Fan ST; Lai CL; Lo CM
    Am J Gastroenterol; 2013 Jun; 108(6):942-8. PubMed ID: 23629601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B.
    Lee HA; Seo YS; Park SW; Park SJ; Kim TH; Suh SJ; Jung YK; Kim JH; An H; Yim HJ; Yeon JE; Byun KS; Um SH
    Clin Mol Hepatol; 2016 Sep; 22(3):382-389. PubMed ID: 27729633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma.
    Kim JH; Sinn DH; Kim K; Kim H; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Gut Liver; 2016 Nov; 10(6):939-947. PubMed ID: 27282264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.